Low-dose mitotane-induced neurological and endocrinological complication in a 5-year-old girl with adrenocortical carcinoma
Mitotane is an adrenolytic drug that exhibits therapeutic effects within a narrow target range (14–20 μg/dL). Various complications develop if the upper limit is exceeded. We present the case of a 5-year-old girl with breast development, acne, and pubic hair who was diagnosed with an adrenal mass th...
Main Authors: | You Joung Heo, Jae Ho Yoo, Yun Soo Choe, Sang Hee Park, Seung Bok Lee, Hyun A Kim, Jung Yoon Choi, Young Ah Lee, Byung Chan Lim, Hee Won Chueh |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society of Pediatric Endocrinology
2022-09-01
|
Series: | Annals of Pediatric Endocrinology & Metabolism |
Subjects: | |
Online Access: | http://e-apem.org/upload/pdf/apem-2142044-022.pdf |
Similar Items
-
Clinical results of the use of mitotane for adrenocortical carcinoma
by: A.A. Kasperlik-Zaluska
Published: (2000-10-01) -
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
by: Nadia Gagnon, et al.
Published: (2023-01-01) -
Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma – case series and literature review
by: Elżbieta Moszczyńska, et al.
Published: (2024-02-01) -
Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
by: Marilda Mormando, et al.
Published: (2023-08-01) -
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01)